Skip to content
Clinical ResearchResearch compoundLimited evidence

THN102

Experimental alertness-boosting drug combination (modafinil and flecainide) that is not yet proven in humans.

NootropicPerformance BoosterEugeroicStimulantFocusDopamineAnti-fatigue

Pharmacology

ClassEugeroic · Stimulant · Focus
Primary targetAstroglial connexins (Cx30/Cx43) + dopamine transporter (DAT)
Targets3 receptor targets
Half-lifeModafinil ~12-15 h; flecainide ~12-27 h
Onset~30-60 min (modafinil component)
EvidenceLimited evidence
Affected systemsDopamineAnti-fatigue

Contents

DETAILED OVERVIEW

What is THN102?

THN102 is an experimental drug combination that pairs the well-known wakefulness-promoting drug modafinil with flecainide, a medicine for heart rhythm disorders. It is not approved for any use and is still in clinical development. It has been studied in sleep deprivation and in the excessive daytime sleepiness that comes with Parkinson's disease.

In the brain, flecainide blocks the connections between astrocytes, the cells that support nerve cells, and this amplifies the effect of modafinil. In animal studies and early human studies, the combination showed better alertness than modafinil alone and also improved working memory, but the human data are still limited and the effect is not proven in people. Headache, insomnia, nausea and dry mouth may occur. Flecainide can also trigger heart rhythm problems, so the combination is contraindicated in heart disease, serious rhythm disorders and after a previous severe skin reaction. There are no safety data for pregnancy and breastfeeding. Because of the modafinil, it counts as prohibited in competitive sport.

Mechanism

Modafinil (DAT) + glial connexin inhibition (flecainide)

Half-life

Modafinil ~12-15 h; low-dose flecainide ~12-27 h

Onset

~30-60 min (modafinil component)

Legal status

Investigational, not approved (Phase 2)

Developer

Theranexus

Receptor profile

  • Dopamine transporter (DAT), modafinil componentModerate
  • Astroglial connexins Cx30/Cx43 (gap junctions), low-dose flecainideModerate
  • Arousal circuit (cortex, striatum, amygdala)Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Headache (modafinil-type, common)
  • Insomnia, sleep disturbance (especially when dosed late in the day)
  • Nausea, dry mouth, decreased appetite (modafinil-type)
  • Anxiety, nervousness, irritability
  • Cardiac effect: flecainide is an antiarrhythmic, proarrhythmic at higher doses (the low dose used in trials was well tolerated)
  • Limited human safety data: investigational combination, full side-effect spectrum unknown

Contraindications · 5

  • Structural or ischemic heart disease, serious arrhythmia (because of the class Ic antiarrhythmic flecainide component)
  • History of serious skin reaction (SJS, TEN, DRESS) or modafinil hypersensitivity
  • Pregnancy and breastfeeding: no clinical safety data, avoid
  • Drug interactions: modafinil CYP3A4 induction (contraceptives), flecainide CYP2D6 metabolism (CYP2D6 inhibitors raise its levels)
  • Not an approved drug, investigational combination; not recommended for unsupervised self-treatment

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

THN102 is an experimental drug pairing the well-known wakefulness booster modafinil with a very low dose of a heart-rhythm medication (flecainide), aiming to sharpen alertness and focus even more than modafinil alone, especially under sleep deprivation. Human trials showed better vigilance than modafinil by itself and improved working memory, but this is still early-stage research, not an established, ready-to-use drug.

Telegram

Have a question about THN102?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.